Navigation Links
ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
Date:5/7/2008

Microbix to Acquire Commercialized Thrombolytic and Related Assets for $17

Million

TUCSON, Ariz., May 7 /PRNewswire-FirstCall/ -- ImaRx Therapeutics, Inc. (Nasdaq: IMRX) today announced that it has signed a letter of intent in which Microbix Biosystems will acquire urokinase inventory and related assets from ImaRx for $17 million in cash. Urokinase is an FDA-approved thrombolytic, or clot-dissolving agent, indicated for the treatment of acute massive pulmonary embolism. ImaRx acquired an approximate four year inventory of the product from Abbott Laboratories and has been selling the product from inventory since 2006.

Bradford A. Zakes, President and CEO of ImaRx, stated, "The proceeds to be generated through this transaction provide ImaRx with a solid source of non- dilutive financing. We are very pleased with the terms under which we have reached agreement with Microbix on the sale of our urokinase asset. Through this transaction, ImaRx will have gained access to operating capital under favorable economic terms that will enable the company to continue the advancement of our core SonoLysis technology."

Under terms of the agreement, Microbix will acquire the urokinase product and related assets for an upfront payment of $12 million plus an additional $5 million upon achievement of an inventory stability milestone. Upon closing, Microbix will assume full responsibility for urokinase, including sales, marketing and regulatory compliance requirements. To facilitate the inventory stability milestone, Microbix will engage ImaRx in a support services agreement.

ImaRx had previously announced in January 2008 that it had signed a letter of intent to partner with Microbix in the transfer
'/>"/>

SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase
2. ImaRx Therapeutics Receives Notification from NASDAQ Regarding Non-Compliance with NASDAQs Minimum Bid Price Requirement
3. ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
4. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
5. ImaRx to Report Corporate Updates and 4Q07 Financial Results
6. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
7. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
8. Cell Therapeutics, Inc. (CTI) to Report 2008 First Quarter and Financial Results on May 8
9. European Regulatory Agency Supports OPAXIO(TM) Brand Name for Cell Therapeutics Lung Cancer Drug
10. HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics
11. United Therapeutics Announces the Results of Its 2008 Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... IL (PRWEB) January 15, 2014 Look ... find hard-working items for the lab, from fluid handling ... Guaranteed-in-Stock (GIS)—ready to ship when you order. , ... Peristaltic Pumps , from the L/S® model for precise ...
(Date:1/15/2014)... SAN JOSE, California , January 15, 2014 ... antibody-drug conjugates for cancer, today announced the appointment of Thomas ... Reynolds has over 20 years, development experience gained in the ... Genetics. "I am delighted to welcome Tom at ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 This webinar ... nonclinical and clinical safety assessment in biosimilars. , Regulatory ... for biosimilar drug development, however the complex nature of ... quality, safety and efficacy extremely challenging. Based on the ...
(Date:1/15/2014)... 15, 2014 More than 5 million ... 1 in 3 seniors will die with Alzheimer’s or ... jaw-dropping figures have shocked many Americans into looking for ... prevent these tragic age-related cognitive disorders. Jonathan Weisman, president ...
Breaking Biology Technology:Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2
... 19 Lightwave Logic, Inc. (OTC Bulletin Board: LWLG ... on the development of electro-optic polymer materials for applications ... today the addition of Anthony J. Cocuzza, PhD to ... in medicinal chemistry and brings a highly developed set ...
... -- What do Saturn and flowers have in common? ... easily recognizable in the natural world. Now, at an ... University of Massachusetts have created a unique set of ... will consistently assemble themselves into these and other complex ...
... FOLD ) announced today that Stephen Bloch, ... from the Company,s Board of Directors effective February 17, ... Amicus, board since 2004. About Amicus Therapeutics ... oral therapeutics known as pharmacological chaperones for the treatment ...
Cached Biology Technology:Lightwave Logic, Inc. Announces the Addition of Anthony J. Cocuzza, PhD to its Technology Team 2Sophisticated nano-structures assembled with magnets 2Sophisticated nano-structures assembled with magnets 3
(Date:4/17/2014)... available in German . ... protection money demanded of him, he can expect his premises ... as fear of the consequences is enough to make restaurant ... birds, which lay their eggs in other birds, nests. If ... parasites take their revenge by destroying the entire nest. Consequently, ...
(Date:4/17/2014)... Yokahama IPCC meeting painted a stark warning on the ... has a greenhouse effect 32 times that of carbon ... that humic substances act as fully regenerable electron acceptors ... held in wetlands instead of being released to the ... is disrupted it may enter into a vicious cycle ...
(Date:4/17/2014)... Pine forests are chock full of wild animals and ... populations of fungi are churning away in the soil, ... , Despite the vital role these fungi play in ... A Stanford-led team of scientists has generated a genetic ... North America. The work was published this week in ...
Breaking Biology News(10 mins):Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3Methane climate change risk suggested by proof of redox cycling of humic substances 2Stanford biologists help solve fungal mysteries 2Stanford biologists help solve fungal mysteries 3
... friend," and rightly so. Consider, for example, that they never ... us when we arrive home, and provide comfort when we ... have worked with and lived next to humans, which some ... the 400 breeds and varieties are unique, but only one ...
... use of a robot to assist with the most ... patient,s risk of developing a rare but serious complication, ... edition of the Journal of Robotic Surgery. ... School at Houston statistically analyzed operative times, length of ...
... Harbor Laboratory (CSHL) professor David Jackson, Ph.D., and a team ... development of the maize plant, commonly known in the United ... understanding of how the different parts of maize arise--important information ... in the U.S. and a mainstay of the global food ...
Cached Biology News:Lessons from the Iditarod 2Lessons from the Iditarod 3Robotic surgery lowers risk of a rare but serious complication of gastric bypass 2Researchers find an essential gene for forming ears of corn 2
... The epitope recognized by ... of isoform 5 of human ... AAH19917.1 (GeneID 9444). The ... isoforms 1, 2, 3, 4, ...
... Normal;heading 1;heading 2;Many ... and experimental situations ... standard transfection and ... systems. ViraPower Lentiviral ...
...
See product name for description....
Biology Products: